Incyte is reportedly nearing a $2 billion acquisition of privately held Star Therapeutics. The agreement includes a $1.25 billion upfront cash payment. Contingent performance milestones could trigger an additional $750 million.
This represents the first major acquisition under Incyte’s new CEO, Bill Meury. The deal aims to diversify the company’s portfolio ahead of the 2028 patent expiration for Jakafi. Jakafi is currently Incyte’s highest-grossing medication.
The acquisition focuses on VGA039, a late-stage monoclonal antibody for von Willebrand disease. Patients receive the treatment through a once-monthly subcutaneous injection. This method provides a more convenient option than traditional frequent infusions. The U.S. Food and Drug Administration has granted VGA039 Fast Track and Breakthrough Therapy designations.